FDA
-
-
-
-
-
-
-
Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update
-
-
-
-
-
-
-
Citius Pharmaceuticals Announces a Registered Direct Offering of $5 Million Priced At-The-Market Under Nasdaq Rules
-
-
-
-
-
-
-
Citius Oncology Announces Preliminary Topline Phase 1 Data from Study of LYMPHIR™ (E7777) Dosing Prior to Commercial CAR‑T Therapy in High‑Risk Diffuse Large B‑Cell Lymphoma
-
-
-
-
-
-
-
Citius Oncology, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update
-
-
-
-
-
-
-
Citius Oncology Expands LYMPHIR™ Distribution to Turkey and Middle East Countries Through Exclusive Agreement with Er-Kim
-
-
-
-
-
-
-
Citius Pharmaceuticals raises $6 million in registered direct offering
-
-
-
-
-
-
-
Citius Oncology Establishes International Access to LYMPHIR™ via Named Patient Programs in Southern Europe
-
326,538 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

